celecoxib has been researched along with Myocardial Ischemia in 12 studies
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease." | 9.12 | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006) |
| "Cyclovirobuxine D is an active compound extracted from Buxus microphylla, which has been used for treating acute myocardial ischemia in China." | 7.74 | Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. ( Chen, S; Hu, D; Liu, X; Wang, Y, 2007) |
| "The results indicate that the volatile anesthetic isoflurane produces a second window of preconditioning against myocardial ischemia and reperfusion injury." | 7.72 | Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. ( Alcindor, D; Kersten, JR; Krolikowski, JG; Ludwig, LM; Pagel, PS; Pratt, PF; Tanaka, K; Warltier, DC, 2004) |
| "We measured the urinary excretion of ATL in 24 patients with both ischaemic heart disease and osteoarthritis, chronically treated with aspirin and co-administered celecoxib 200 mg b." | 5.14 | Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. ( De Caterina, R; Renda, G; Romano, M; Zurro, M, 2010) |
| "We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease." | 5.12 | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006) |
| " We hypothesize that hypercholesterolemia and ischemia may alter the myocardial response to the cyclooxygenase-2 inhibitor celecoxib." | 3.77 | Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition. ( Burgess, T; Chu, LM; Lassaletta, A; Liu, Y; Robich, MP; Sellke, FW; Sellke, N, 2011) |
| "Cyclovirobuxine D is an active compound extracted from Buxus microphylla, which has been used for treating acute myocardial ischemia in China." | 3.74 | Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. ( Chen, S; Hu, D; Liu, X; Wang, Y, 2007) |
| "The results indicate that the volatile anesthetic isoflurane produces a second window of preconditioning against myocardial ischemia and reperfusion injury." | 3.72 | Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. ( Alcindor, D; Kersten, JR; Krolikowski, JG; Ludwig, LM; Pagel, PS; Pratt, PF; Tanaka, K; Warltier, DC, 2004) |
| "Pretreatment with celecoxib resulted in a significant reduction in TNF-α levels and an increase in NO(x) and NOS levels compared with the AMI group." | 1.38 | Low-dose celecoxib improves coronary function after acute myocardial ischaemia in rabbits. ( Bi, XY; He, X; Li, DL; Liu, JJ; Ma, X; Yu, XJ; Zang, WJ; Zhang, HL; Zhao, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wan, X | 1 |
| Meng, J | 1 |
| Dai, Y | 1 |
| Zhang, Y | 1 |
| Yan, S | 1 |
| Renda, G | 2 |
| Zurro, M | 2 |
| Romano, M | 1 |
| De Caterina, R | 2 |
| Robich, MP | 3 |
| Chu, LM | 3 |
| Feng, J | 2 |
| Burgess, TA | 1 |
| Laham, RJ | 1 |
| Bianchi, C | 2 |
| Sellke, FW | 3 |
| Lassaletta, A | 1 |
| Burgess, T | 2 |
| Liu, Y | 2 |
| Sellke, N | 1 |
| Xu, SH | 1 |
| Zhao, M | 2 |
| He, X | 1 |
| Bi, XY | 1 |
| Zhang, HL | 1 |
| Yu, XJ | 1 |
| Liu, JJ | 1 |
| Li, DL | 1 |
| Ma, X | 1 |
| Zang, WJ | 1 |
| Arnaud, C | 1 |
| Joyeux-Faure, M | 1 |
| Godin-Ribuot, D | 1 |
| Ribuot, C | 1 |
| Tanaka, K | 1 |
| Ludwig, LM | 1 |
| Krolikowski, JG | 1 |
| Alcindor, D | 1 |
| Pratt, PF | 1 |
| Kersten, JR | 1 |
| Pagel, PS | 1 |
| Warltier, DC | 1 |
| Tacconelli, S | 1 |
| Capone, ML | 1 |
| Sacchetta, D | 1 |
| Santarelli, F | 1 |
| Sciulli, MG | 1 |
| Zimarino, M | 1 |
| Grana, M | 1 |
| D'Amelio, E | 1 |
| Price, TS | 1 |
| Patrono, C | 1 |
| Patrignani, P | 1 |
| Liu, X | 2 |
| Zhou, Z | 1 |
| Feng, X | 1 |
| Jia, Z | 1 |
| Jin, Y | 1 |
| Xu, J | 1 |
| Hu, D | 1 |
| Wang, Y | 2 |
| Chen, S | 1 |
| Shinmura, K | 1 |
| Tang, XL | 1 |
| Xuan, YT | 1 |
| Liu, SQ | 1 |
| Takano, H | 1 |
| Bhatnagar, A | 1 |
| Bolli, R | 1 |
2 trials available for celecoxib and Myocardial Ischemia
| Article | Year |
|---|---|
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors.
Topics: Aged; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Humans; Ibuprofen; | 2010 |
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Celecoxib; Double-Blind Method; Drug Adminis | 2006 |
10 other studies available for celecoxib and Myocardial Ischemia
| Article | Year |
|---|---|
Visualization of network target crosstalk optimizes drug synergism in myocardial ischemia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Celecoxib; Cells, Cultured; Curcumin | 2014 |
Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.
Topics: Angiogenic Proteins; Animals; Apoptosis; Blood Pressure; Celecoxib; Collateral Circulation; Coronary | 2010 |
Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition.
Topics: Animals; Celecoxib; Comorbidity; Cyclooxygenase 2 Inhibitors; Epoprostenol; Heart; Hemodynamics; Hum | 2011 |
Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Heart; Hypercholesterolemia; Male; Myocardial Ischemi | 2012 |
Low-dose celecoxib improves coronary function after acute myocardial ischaemia in rabbits.
Topics: Acute Disease; Animals; Celecoxib; Coronary Vessels; Cyclooxygenase 2 Inhibitors; Dose-Response Rela | 2012 |
COX-2: an in vivo evidence of its participation in heat stress-induced myocardial preconditioning.
Topics: Animals; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2003 |
Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2.
Topics: Anesthetics, Inhalation; Animals; Blood Pressure; Blotting, Western; Celecoxib; Coronary Circulation | 2004 |
Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Erythropoietin; Ischemic Precondi | 2006 |
Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis.
Topics: Acute Disease; Animals; Animals, Newborn; Celecoxib; Cell Hypoxia; Cell Survival; Cells, Cultured; C | 2007 |
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2000 |